May 2024
06 Aug 2024
The global osteoporosis treatment market is estimated to be worth around USD 19.84 billion by 2033 and is poised to grow at a CAGR of 5% during the forecast period. Due to the growing geriatric population and the success rate of advanced treatment methods, this market is rising rapidly.
The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/3419
The osteoporosis treatment market is growing rapidly due to rising cases of bone issues in people of almost all age groups. Osteoporosis is the condition where the bone gets weakened due to nutrition deficiency. In the entire life cycle of a human being, the bone gets absorbed and replaces bone tissues; in osteoporosis case, the person’s body is unable to create new bone tissues with the replacement of old tissues.
This is caused by the body's lack of calcium and vitamin D, which increases the risk of fractures. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Osteoporosis is a silent disease as it has no such symptoms, and one suffering from this disease can not even know it unless the bone breaks. The major reason behind the fracture in postmenopausal women and old men is due to osteoporosis. Hips, wrists, and vertebrae in the spine are the most commonly seen fractures.
Rising investment in this osteoporosis treatment market is contributing significantly to its growth. Some of the major players contributing to the growth are Amgen Inc., Novartis AG, Cipla Inc., Pfizer Inc., Merck Sharp, and Dohme. Many such players are constantly working on research and bringing revolutionary changes.
Research and launch of new treatment methods driving the osteoporosis treatment market
Osteoporosis is a commonly found disease in several people because of various factors such as age, sex, race, family history, changes in hormones, medication, diet, lifestyle, and body size. Research groups and scientists are actively working on finding better solutions to improve the results of this disease. It is found in studies that in women after menopause, lower estrogen levels, extreme physical activities, and low testosterone levels in men are also responsible for osteoporosis. According to the National Library of Medicine, 1 in every 3 women who are above 50 years of age and 1 in 5 men are experiencing osteoporosis fracture risk.
In total, approximately 200 million people are suffering from osteoporosis worldwide. Many companies are collaborating to research the most appropriate treatment methods that are helpful for patients of all age groups. For instance, UCB and Amgen have declared that by following the re-examination method, the Committee for Medicinal Products for Human Use of the European Medicines Agency provided a positive opinion for EVENITY, which is developed for the treatment of postmenopausal women facing the risk of severe osteoporosis.
Continuous research in this field is influencing the market to grow rapidly. For instance, in November 2023, Apotex Corp., which is a company constantly improving access to medicines for worldwide patients, launched Teriparatide injections for patients suffering from osteoporosis. The major concern is for women who are suffering from this disease post-menopause, and various companies are constantly working on this around the various corners of the world. For instance, Chugai Pharmaceutical Co. Ltd., which is a Japan-originated drug manufacturer operating, launched Edirol in its branch in China; Edirol works as the base drug for the treatment of osteoporosis.
The adverse effects of such advanced medications are the restraining factors of the osteoporosis treatment market. The rising fear among people seeing the effect, as also published by studies, is hindering the growth of this market.
Recent Development by Entera Bio Ltd.
Recent Development by Teva Pharmaceuticals
Asia Pacific is expected to be the fastest-growing region during the forecast period due to the continuous progress of countries like Japan, China, and others. For instance, in January 2023, Teijin Pharma, which is a Japan-based pharmaceutical company developing business in pharmaceutical and home healthcare equipment, announced the start of selling abaloparatide acetate, which is used for the treatment of osteoporosis. Enhancing availability helps people know about the medication for the disease, hence contributing to the growth of the osteoporosis treatment market. For instance, in October 2023, at the Peking University School and Hospital for Stomatology, China, scientists used deep learning methods to study dihydroartemisinin (DHA), which is popularly known as an anti-malarial drug but holds the potential to treat osteoporosis patients.
North America dominated the osteoporosis treatment market in 2023 due to several factors, such as the rising geriatric population, investment in research work, advancement in medication, and many more. For instance, according to the Bone Health & Osteoporosis Foundation, in America, approximately 10 million people suffer from osteoporosis, and 44 million Americans have low bone density. and predicted that by the end of 2025, 3 million fractures will be due to osteoporosis, which will ultimately result in a $25.3 billion cost in its treatment.
Enhancing diagnosis methods and clinical trials increases the osteoporosis treatment market
The worldwide players are constantly working on enhanced methods of osteoporosis treatment, and with this, the number of patients suffering from this disease is also increasing. Recently, the Food and Drug Administration (FDA) of the US has approved Forteo, which is the generic version of teriparatide for the treatment of osteoporosis; this drug was developed by the company Ambio and Teva. Researchers consider this highly effective for osteoporosis. Thus, growing developments in this field and the introduction of new and effective methods increase the potential of the market.
| Report Attribute | Key Statistics |
| Market Revenue in 2024 | USD 12.79 Billion |
| Market Revenue by 2033 | USD 19.84 Billion |
| CAGR | 5% |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2023 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Market Segmentation
By Drug Class
By Route of Administration
By Distribution Channel
Buy this Research Report@ https://www.precedenceresearch.com/checkout/3419
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308
May 2024
February 2024
February 2024
March 2024